Japanese pharmaceutical giant Takeda said it has completed construction of its new $111 million manufacturing plant on the outskirts of Berlin in Oranienburg, Germany.
Construction of the facility was announced by Takeda in 2014 as part of the company’s plan to streamline the global manufacturing of its solid dosage form pharmaceutical products from its plant in Osaka to the Oranienburg facility and Hikari plant in Japan, the company said.
The 21,400-square-meter Oranienburg plant is scheduled to open by the end of the year and has already created 180 new jobs.
Production at the new facility is expected to supply about 100 countries globally and will include drugs used to treat diseases for in the areas of gastroenterology, central nervous and cardiovascular systems.
“We continuously invest in our facilities to advance our technologies in order to ensure a stable supply of high-quality drug products to patients around the world,” Thomas Wozniewski, Takeda’s global manufacturing and supply officer, said in a statement.
Germany has been the focus of a lot of Takeda manufacturing investment. In November, the drugmaker said it would “immediately” begin construction on a $106 million plant at its manufacturing site in Singen, Germany. That plant, which is expected to be completed in 2019, will focus on Takeda’s big push into a vaccine to treat dengue.
If approved, analysts have said Takeda’s dengue vaccine (TAK-003) could dominate market share by 2020, with some industry predictions pegging dengue vaccines to reach $1 billion or more in yearly sales.